Literature DB >> 12168964

Genetic epidemiologic aspects of gastric cancer in Iceland.

Albert Kjartansson Imsland1, Bjarki Jónsson Eldon, Sturla Arinbjarnarson, Valgarğur Egilsson, Hrafn Tulinius, Laufey Tryggvadóttir, Reynir Arngrímsson, Jónas Magnússon.   

Abstract

BACKGROUND: Association between gastric cancer and environmental factors (diet and infections) has been established, and genetic changes are well described in adenocarcinomas of the stomach. Less is known about clinical features of hereditary gastric cancer and whether the disease is associated with family clustering. STUDY
DESIGN: Family trees of patients diagnosed with gastric cancer in Iceland between 1955 and 1999 were identified in the Genealogical Database of the University of Iceland. All probands with age of onset younger than 60 years were used in the study. Families of all probands (n = 455 men and 161 women) were traced to third degree. Through linkage of the genealogic data obtained by the Icelandic Cancer Registry (between 1955 and 1999), all reported cancers were identified in those families. The expected number of cases was calculated using age-specific population rates in Iceland.
RESULTS: A relative risk (RR) of 2.2 (95% confidence interval [CI] = 1.6-3.0) and 1.3 (95% CI = 1.0-1.7) for the gastric cancer risk was observed among 2,846 first- and 8,658 second-degree relatives of male probands. For female probands the corresponding relative risks were 1.6 (95% CI = 1.1-2.6, n = 7,396) and 1.4 (95% CI = 0.9-2.0, n = 2,764). The increased risk was more pronounced for relatives of men and women diagnosed with gastric cancer before the age of 50 years. A minor difference in relative risk was found between relatives of probands who were diagnosed with intestinal type or diffuse type gastric cancer. Fifty-eight families with two or more relatives with cancer were identified. In 32 families 2 relatives with gastric cancer were identified and in 26 families 3 or more relatives had gastric cancer.
CONCLUSIONS: Relatives of gastric cancer patients have two- to three-fold increased risk of developing gastric cancer. The risk is elevated for both genders.

Entities:  

Mesh:

Year:  2002        PMID: 12168964     DOI: 10.1016/s1072-7515(02)01215-2

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  6 in total

Review 1.  [Prophylactic gastric surgery].

Authors:  H Vogelsang; K Ott; J Mehler; G Keller; J R Siewert
Journal:  Chirurg       Date:  2005-12       Impact factor: 0.955

2.  Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report.

Authors:  P Malfertheiner; F Megraud; C O'Morain; F Bazzoli; E El-Omar; D Graham; R Hunt; T Rokkas; N Vakil; E J Kuipers
Journal:  Gut       Date:  2006-12-14       Impact factor: 23.059

3.  Population screening for hereditary and familial cancer syndromes in Valka district of Latvia.

Authors:  Andrejs Vanags; Ilze Strumfa; Andris Gardovskis; Viktors Borošenko; Arnis Aboliņš; Uldis Teibe; Genadijs Trofimovičs; Edvīns Miklaševičs; Jānis Gardovskis
Journal:  Hered Cancer Clin Pract       Date:  2010-10-29       Impact factor: 2.857

4.  Clinicopathologic characteristics of gastric cancer in a young patient population.

Authors:  Antonio Ramos-De la Medina; Noel Salgado-Nesme; Gonzalo Torres-Villalobos; Heriberto Medina-Franco
Journal:  J Gastrointest Surg       Date:  2004 Mar-Apr       Impact factor: 3.452

5.  Schizophrenia, cancer and obstetric complications in an evolutionary perspective-an empirically based hypothesis.

Authors:  Antonio Preti; Daniel R Wilson
Journal:  Psychiatry Investig       Date:  2010-12-15       Impact factor: 2.505

6.  Cancer as a complex phenotype: pattern of cancer distribution within and beyond the nuclear family.

Authors:  Laufey T Amundadottir; Sverrir Thorvaldsson; Daniel F Gudbjartsson; Patrick Sulem; Kristleifur Kristjansson; Sigurdur Arnason; Jeffrey R Gulcher; Johannes Bjornsson; Augustine Kong; Unnur Thorsteinsdottir; Kari Stefansson
Journal:  PLoS Med       Date:  2004-12-28       Impact factor: 11.069

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.